Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Frank, 1993, Efficacy of treatments for major depression, Psychopharmacol Bull, 29, 457
Fava, 1996, Definition and epidemiology of treatment-resistant depression, Psychiatr Clin North Am, 19, 179, 10.1016/S0193-953X(05)70283-5
Agosti, 1999, Predictors of persistent social impairment among recovered depressed outpatients, J Affect Disord, 55, 215, 10.1016/S0165-0327(98)00200-6
Weissman, 1991, Affective disorders, 53
Kessler, 1994, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey, Arch Gen Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002
Depression Guideline Panel. Clinical practice guideline. Number 5. Depression in primary care, vol. 1. Detection and diagnosis. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93–0550; 1993.
Mueller, 1996, Recovery, chronicity, and levels of psychopathology in major depression, Psychiatr Clin North Am, 19, 85, 10.1016/S0193-953X(05)70275-6
American Psychiatric Association, 1994
Keller, 1995, Results of the DSM-IV Mood Disorders Field Trial, Am J Psychiatry, 152, 843, 10.1176/ajp.152.6.843
Judd, 1998, A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders, Arch Gen Psychiatry, 55, 694, 10.1001/archpsyc.55.8.694
Thase, 1994, Refractory depression: relevance of psychosocial factors and therapies, Psychiatr Ann, 24, 232, 10.3928/0048-5713-19940501-09
Depression Guideline Panel. Clinical practice guideline. Number 5. Depression in primary care, vol. 2. Treatment of major depression. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93–0551;1993.
Wells, 1989, The functioning and well-being of depressed patients: results from the Medical Outcomes Study, JAMA, 262, 914, 10.1001/jama.1989.03430070062031
Murray, 1996, Evidence-based health policy: lessons from the Global Burden of Disease Study, Science, 274, 740, 10.1126/science.274.5288.740
Greenberg, 1993, The economic burden of depression in 1990, J Clin Psychiatry, 54, 405
Simon, 1998, Health care costs of primary care patients with recognized depression, Arch Gen Psychiatry, 52, 850, 10.1001/archpsyc.1995.03950220060012
Judd, 1997, The clinical course of unipolar major depressive disorders, Arch Gen Psychiatry, 54, 989, 10.1001/archpsyc.1997.01830230015002
Judd, 1996, Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population, Am J Psychiatry, 153, 1411, 10.1176/ajp.153.11.1411
Miller, 1998, The treatment of chronic depression,, J Clin Psychiatry, 59, 608, 10.4088/JCP.v59n1108
McCombs, 1993, Pharmacy-enforced outpatient drug treatment protocols: a case study of Medical restrictions for cefaclor, Ann Pharmacother, 27, 155, 10.1177/106002809302700203
Jarrett, 1994, Short-term psychotherapy of depressive disorders: current status and future directions, Psychiatry: Interpers Biol Process, 57, 115, 10.1080/00332747.1994.11024675
Frank, 1991, Conceptualization and rationale for consensus definitions of response, remission, recovery, relapse and recurrence in major depressive disorder, Arch Gen Psychiatry, 48, 851, 10.1001/archpsyc.1991.01810330075011
Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56
Hamilton, 1967, Development of a rating scale for primary depressive illness, Br J Soc Clin Psychol, 6, 278, 10.1111/j.2044-8260.1967.tb00530.x
Riso, 1997, A prospective test of criteria for response, remission, relapse, recovery, and recurrence in patients treated with cognitive behavior therapy, J Affect Disord, 43, 131, 10.1016/S0165-0327(96)01420-6
Akiskal, 1981, Subaffective disorders: dysthymic, cyclothymic, and bipolar II disorders in the “borderline” realm, Psychiatr Clin North Am, 4, 25, 10.1016/S0193-953X(18)30935-3
Howland, 1993, General health, health care utilization, and medical comorbidity in dysthymia, Int J Psychiatr Med, 23, 211, 10.2190/AXCU-P704-23XQ-CQTR
American Psychiatric Association, 1993, Practice guideline for major depressive disorder in adults, Am J Psychiatry, 150, 1
American Psychiatric Association, 2000, Practice guideline for the treatment of patients with major depressive disorder, Am J Psychiatry, 157, 1
Crismon, 1999, The Texas Medication Algorithm Project. Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder, J Clin Psychiatry, 60, 142, 10.4088/JCP.v60n0302
Gilbert, 1998, Texas Medication Algorithm Project: definitions, rationale and methods to develop medication algorithms, J Clin Psychiatry, 59, 345, 10.4088/JCP.v59n0702
Rush, 2000, The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms, Int J Methods Psychiatric Res, 9, 49, 10.1002/mpr.79
Rush, 1995, From scientific knowledge to the clinical practice of psychopharmacology: Can the gap be bridged?, Psychopharmacol Bull, 31, 7
Fava, 1994, Continuation and maintenance treatments of major depressive disorder, Psychiatr Ann, 24, 281, 10.3928/0048-5713-19940601-07
Keller, 1998, The treatment of chronic depression,, J Clin Psychiatry, 59, 598, 10.4088/JCP.v59n1107
Fava, 1996, Pharmacological strategies for treatment-resistant major depression, 3
Rosenbaum, 2001, Treatment-resistant mood disorders, vol. 2, 1307
Byrne, 1997, Psychiatrists' responses to failure of maintenance therapy with antidepressants, Psychiatr Serv, 48, 835, 10.1176/ps.48.6.835
Frank, 1990, Three-year outcomes for maintenance therapies in recurrent depression, Arch Gen Psychiatry, 47, 1093, 10.1001/archpsyc.1990.01810240013002
Frank, 1992, Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression, Psychopharmacol Bull, 28, 231
Poirier, 1999, Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomized comparison, Br J Psychiatry, 175, 12, 10.1192/bjp.175.1.12
Thase, 1995, Treatment-resistant depression, 1081
Thase, 1997, When at first you don't succeed: sequential strategies for antidepressant nonresponders, J Clin Psychiatry, 58, 23
Bridges, 1983, …and a small dose of an antidepressant might help, Br J Psychiatry, 142, 626, 10.1192/bjp.142.6.626
Brugha, 1992, Antidepressants may not assist recovery in practice: a naturalistic prospective study, Acta Psychiatr Scand, 86, 5, 10.1111/j.1600-0447.1992.tb03218.x
Fauman, 1980, Tricyclic antidepressant prescription by general hospital physicians, Am J Psychiatry, 237, 490
Johnson, 1974, A study of the use of antidepressant medication in general practice, Br J Psychiatry, 125, 186, 10.1192/bjp.125.2.186
Keller, 1982, Treatment received by depressed patients, JAMA, 248, 1848, 10.1001/jama.1982.03330150034019
Ketai, 1976, Family practitioners knowledge about treatment of depressive illness, JAMA, 235, 2600, 10.1001/jama.1976.03260500016018
Kotin, 1973, Drug treatment of depressed patients referred for hospitalization, Am J Psychiatry, 130, 1139, 10.1176/ajp.130.10.1139
Schatzberg, 1983, Survey of depressed patients who failed to respond to treatment, 73
Remick RA, Barton JS, Patterson B. On so-called treatment-resistant depression. Presented at 51st Annual Meeting of the Royal Collage of Physicians and Surgeons of Canada. Québec City, Québec, Canada, September 1982.
Nierenberg, 1990, After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression, J Affect Disord, 18, 167, 10.1016/0165-0327(90)90033-5
Ravaris, 1976, A multiple dose controlled study of phenelzine in depression-anxiety states, Arch Gen Psychiatry, 33, 347, 10.1001/archpsyc.1976.01770030057008
Simpson, 1976, Two dosages of imipramine in hospitalized endogenous and neurotic depressives, Arch Gen Psychiatry, 33, 1093, 10.1001/archpsyc.1976.01770090083008
Tyrer, 1980, Clinical and pharmacokinetic factors affecting response to phenelzine, Br J Psychiatry, 136, 359, 10.1192/bjp.136.4.359
Watt, 1972, Metabolism, anticholinergic effects and therapeutic effects on outcome of desmethylimipramine in depressive illness, Psychol Med, 2, 397, 10.1017/S0033291700045219
Dornseif, 1989, Effect of dose escalation after low-dose fluoxetine therapy, Psychopharmacol Bull, 25, 71
Preskorn, 1995, Sertraline 50 mg daily; the optimal dose in the treatment of depression, Int Clin Psychopharmacol, 10, 129, 10.1097/00004850-199510030-00001
Schweitzer, 1990, What constitutes an adequate antidepressant trial for fluoxetine?, J Clin Psychiatry, 51, 8
Fava, 1992, High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine, J Affect Disord, 25, 229, 10.1016/0165-0327(92)90080-P
Fava, 1994, Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study, Am J Psychiatry, 151, 1372, 10.1176/ajp.151.9.1372
Kelsey, 1996, Dose-response relationship with venlafaxine, J Clin Psychopharmacol, 16, 21S, 10.1097/00004714-199606002-00005
Fava, 2001, Augmentation and combination strategies in treatment-resistant depression, J Clin Psychiatry, 62, 4
Ontiveros, 1991, Refractory depression: the addition of lithium to fluoxetine or desipramine, Acta Psychiatr Scand, 83, 188, 10.1111/j.1600-0447.1991.tb05522.x
Baumann, 1996, A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation, J Clin Psychopharmacol, 16, 307, 10.1097/00004714-199608000-00006
Cournoyer G, de Montigny C, Oulette J, et al. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. Presented at the XIVth Congress of the Collegium Internationale Neuropsychopharmacologicum (CINP). Florence, Italy, June 19–23, 1984.
de Montigny, 1983, Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system, Arch Gen Psychiatry, 40, 1327, 10.1001/archpsyc.1983.01790110069012
Heninger, 1983, Lithium carbonate augmentation of antidepressant action: an effective prescription for treatment refractory depression, Arch Gen Psychiatry, 40, 1335, 10.1001/archpsyc.1983.01790110077013
Joffe, 1993, An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression, J Clin Psychiatry, 54, 269
Kantor, 1986, The benefit of lithium carbonate adjunct in refractory depression: fact or fiction?, Can J Psychiatry, 31, 416, 10.1177/070674378603100506
Katona, 1995, Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine, Br J Psychiatry, 166, 80, 10.1192/bjp.166.1.80
Schopf, 1989, Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition, Pharmacopsychiatry, 22, 183, 10.1055/s-2007-1014603
Stein, 1988, Double-blind trial of lithium carbonate in tricyclic resistant depression, 35
Stein, 1993, Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses, Br J Psychiatry, 162, 634, 10.1192/bjp.162.5.634
Zusky, 1988, Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study, J Clin Psychopharmacol, 8, 120, 10.1097/00004714-198804000-00007
Prange, 1996, Novel uses of thyroid hormone in patients with affective disorders, Thyroid, 6, 537, 10.1089/thy.1996.6.537
Aronson, 1996, Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis, Arch Gen Psychiatry, 53, 842, 10.1001/archpsyc.1996.01830090090013
Bouwer, 1997, Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors in severe treatment-refractory depression, South Afr Med J, 87, 534
Dimitriou, 1998, Buspirone augmentation of antidepressant therapy, J Clin Psychopharmacol, 18, 465, 10.1097/00004714-199812000-00009
Jacobsen, 1991, A possible augmentation of antidepressant response by buspirone, J Clin Psychiatry, 52, 217
Landen, 1998, A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression, J Clin Psychiatry, 59, 664, 10.4088/JCP.v59n1204
Appelberg, 2001, Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study, J Clin Psychiatry, 62, 448, 10.4088/JCP.v62n0608
Fredman, 2000, Partial response, non-response, and relapse on SSRIs in major depression: a survey of current “next-step” practices, J Clin Psychiatry, 61, 403, 10.4088/JCP.v61n0602
Bodkin, 1997, Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy, J Clin Psychiatry, 58, 137, 10.4088/JCP.v58n0401
Marshall, 1996, Paroxetine/bupropion combination treatment for refractory depression, J Clin Psychopharmacol, 16, 80, 10.1097/00004714-199602000-00016
Marshall, 1995, Bupropion and sertraline combination treatment in refractory depression, J Psychopharmacol, 9, 284, 10.1177/026988119500900313
Spier, 1998, Use of bupropion with SRIs and venlafaxine, Depress Anxiety, 7, 73, 10.1002/(SICI)1520-6394(1998)7:2<73::AID-DA4>3.0.CO;2-6
Carpenter, 1999, Mirtazapine augmentation in the treatment of refractory depression, J Clin Psychiatry, 60, 45, 10.4088/JCP.v60n0110
Carpenter, 2002, A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression, Biol Psychiatry, 51, 183, 10.1016/S0006-3223(01)01262-8
Debonnel G, Gobbi G, Turcotte J, et al. The α2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 10–14, 2000.
Fava, 1998, Prevention of recurrent depression with cognitive therapy: preliminary findings, Arch Gen Psychiatry, 55, 816, 10.1001/archpsyc.55.9.816
Charney, 1998, Monoamine dysfunction and the pathophysiology and treatment of depression, J Clin Psychiatry, 59, 11
van Praag, 1990, Monoamines and abnormal behaviour: a multi-aminergic perspective, Br J Psychiatry, 157, 723, 10.1192/bjp.157.5.723
Fulgum, 1996, Screening and treating depressed patients: a comparison of two controlled citalopram trials across treatment settings: hospitalized patients versus patients treated by their family doctors, Acta Psychiatr Scand, 94, 18, 10.1111/j.1600-0447.1996.tb09819.x
McGrath, 1994, Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant, J Clin Psychiatry, 55, 336
McGrath, 1993, A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression, Am J Psychiatry, 150, 118, 10.1176/ajp.150.1.118
Thase, 1992, Treatment of imipramine-resistant recurrent depression,, Am J Psychiatry, 149, 195
Beasley, 1990, Fluoxetine in tricyclic refractory major depressive disorder, J Affect Disord, 20, 193, 10.1016/0165-0327(90)90144-W
Fava, 2000, Management of nonresponse and intolerance: switching strategies, J Clin Psychiatry, 61, 10
Joffe, 1996, Response to an open trial of a second SSRI in major depression, J Clin Psychiatry, 57, 114
Thase, 1997, Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline, J Clin Psychiatry, 58, 16, 10.4088/JCP.v58n0103
Thase, 2001, Citalopram treatment of fluoxetine nonresponders, J Clin Psychiatry, 62, 683, 10.4088/JCP.v62n0904
Guy W. ECDEU assessment manual for psychopharmacology revised, 1976. Rochville, MD: U.S. Department of Health, Education and Welfare. DHEW Publication No. (ADM) 76-338; 1976. p. 218.
Thase, 2002, Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression, Arch Gen Psychiatry, 59, 233, 10.1001/archpsyc.59.3.233
Nierenberg, 1994, Venlafaxine for treatment-resistant unipolar depression, J Clin Psychopharmacol, 14, 419, 10.1097/00004714-199412000-00008
de Montigny, 1999, Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial, J Clin Psychopharmacol, 19, 401, 10.1097/00004714-199910000-00003
Fava, 2001, Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial, J Clin Psychiatry, 62, 413, 10.4088/JCP.v62n0603
Rush, 1999, Implementing guidelines and systems of care: experiences with the Texas Medication Algorithm Project (TMAP), J Pract Psychiatry Behav Health, 5, 75, 10.1097/00131746-199903000-00002
Rush, 1999, Linking efficacy and effectiveness research in the evaluation of psychotherapies, 26
Kobak, 1999, Computerized assessment of depression and anxiety over the telephone using Interactive Voice Response, MD Comput, 16, 61
Basco, 1995, Compliance with pharmacotherapy in mood disorders, Psychiatr Ann, 25, 269, 10.3928/0048-5713-19950501-03
Paykel, 1999, Prevention of relapse in residual depression by cognitive therapy: a controlled trial, Arch Gen Psychiatry, 56, 829, 10.1001/archpsyc.56.9.829
Williams, 1988, A structured interview guide for the Hamilton Depression Rating Scale, Arch Gen Psychiatry, 45, 742, 10.1001/archpsyc.1988.01800320058007
Rush, 1986, The Inventory for Depressive Symptomatology (IDS): preliminary findings, Psychiatry Res, 18, 65, 10.1016/0165-1781(86)90060-0
Rush, 1996, The Inventory of Depressive Symptomatology (IDS): psychometric properties, Psychol Med, 26, 477, 10.1017/S0033291700035558
Ware, 1996, A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity, Med Care, 34, 220, 10.1097/00005650-199603000-00003
Reilly, 1993, The validity and reproducibility of a work productivity and activity impairment instrument, Pharmacoeconomics, 4, 353, 10.2165/00019053-199304050-00006
Mundt JC, Kobak KA, Greist JH, Marks IM. Work and social adjustment scale: an alternative quality-of-life instrument. Presented at the 39th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU). Boca Raton, FL, June 1–4, 1999.
Ware, 1992, The MOS 36-item short-form health survey (SF-36), Med Care, 30, 473, 10.1097/00005650-199206000-00002
Endicott, 1993, Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q): a new measure, Psychopharmacol Bull, 29, 321
Clark, 1996, Measuring hospital use without claims: a comparison of patient and provider reports, Health Serv Res, 31, 153
Dresser, 1997, Clinical quality measurement: comparing chart review and automated methodologies, Med Care, 35, 539, 10.1097/00005650-199706000-00001
Kashner, 1998, Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs, Med Care, 36, 1324, 10.1097/00005650-199809000-00005
Kashner, 1992, An analysis of panel data: the impact of a psychiatric consultation letter on the expenditures and outcomes of care for patients with somatization disorder, Med Care, 30, 811, 10.1097/00005650-199209000-00005
Magaziner, 1988, Patient-proxy response comparability on measures of patient health and functional status, J Clin Epidemiol, 41, 1065, 10.1016/0895-4356(88)90076-5
Quam, 1993, Using claims data for epidemiologic research: the concordance of claim-based criteria with the medical record and patient survey for identifying a hypertensive population, Med Care, 31, 498, 10.1097/00005650-199306000-00003
Kashner, 1999, Measuring costs of guideline-drive mental health care: The Texas Medication Algorithm Project, J Ment Health Policy Econ, 2, 111, 10.1002/(SICI)1099-176X(199909)2:3<111::AID-MHP52>3.0.CO;2-M
Rush, 1999, Medication treatment of the severely and persistently mentally ill: The Texas Medication Algorithm Project, J Clin Psychiatry, 60, 142, 10.4088/JCP.v60n0503
Keller MB. Pharmacotherapy and psychotherapy: New data on the long-term treatment of chronic depression. Presented at the 154th Annual Meeting of the American Psychiatric Association. New Orleans LA, May 5–10, 2001
Lavori, 2001, Strengthening clinical effectiveness trials: equipoise-stratified randomization, Biol Psychiatry, 50, 792, 10.1016/S0006-3223(01)01223-9
Cooper-Patrick, 1997, Identification of patient attitudes and preferences regarding treatment of depression, J Gen Intern Med, 12, 431, 10.1046/j.1525-1497.1997.00075.x
Eisenthal, 1979, “Adherence” and the negotiated approach to patienthood, Arch Gen Psychiatry, 36, 393, 10.1001/archpsyc.1979.01780040035003
Frank, 1995, Alliance not compliance: a philosophy of outpatient care, J Clin Psychiatry, 56, 11
Elkin, 1989, National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments, Arch Gen Psychiatry, 46, 971, 10.1001/archpsyc.1989.01810110013002
Ezra, 1997, An analysis of treatment preferences in patients of a late life depression clinic, Dissertation Abstracts International: Section B: The Sciences and Engineering, 57, 5324
Rush, 2001, Strategies and tactics in the treatment of depression, vol. 2, 1417
Meterissian, 1989, Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided?, J Clin Psychopharmacol, 9, 334, 10.1097/00004714-198910000-00004
Quitkin, 1984, Duration of antidepressant drug treatment, what is an adequate trial?, Arch Gen Psychiatry, 41, 238, 10.1001/archpsyc.1984.01790140028003
Stassen, 1993, Time course of improvement under antidepressant treatment: a survival-analytic approach, Eur Neuropsychopharmacol, 3, 127, 10.1016/0924-977X(93)90264-M
Hirschfeld, 1997, The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression, JAMA, 277, 333, 10.1001/jama.1997.03540280071036
Davis, 1995, Changing physician performance. A systematic review of the effect of continuing medical education strategies, JAMA, 274, 700, 10.1001/jama.1995.03530090032018
Evans, 1986, Does a mailed continuing education program improve physician performance?, JAMA, 255, 501, 10.1001/jama.1986.03370040075027
Headrick, 1992, Efforts to improve compliance with the national Cholesterol Education Program guidelines, Arch Intern Med, 152, 2490, 10.1001/archinte.1992.00400240104017
Margolis, 1992, Computerized algorithms and pediatricians' management of common problems in a community clinic, Acad Med, 67, 282, 10.1097/00001888-199204000-00021
Tierney, 1986, Delayed feedback of physician performance versus immediate reminders to perform preventive care: effects on physician compliance, Med Care, 24, 659, 10.1097/00005650-198608000-00001
Anderson, 1994, Changing clinical practice: prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism, Arch Intern Med, 154, 669, 10.1001/archinte.1994.00420060103011
Gemson, 1995, Putting prevention into practice: impact of a multifaceted physician education program on preventive services in the inner city, Arch Fam Med, 155, 2210
Hunt, 1998, Effects of computer-based clinical decision support systems on physician performance and patient outcomes, JAMA, 280, 1339, 10.1001/jama.280.15.1339
Francis, 1996, The Expert Consensus Guideline Series: treatment of schizophrenia, J Clin Psychiatry, 57, 1
Francis, 1996, The Expert Consensus Guideline Series: treatment of bipolar disorder, J Clin Psychiatry, 57, 1
Schoenbaum, 1990, Algorithm based improvement of clinical quality, BMJ, 301, 1374, 10.1136/bmj.301.6765.1374
Guiterrez, 1994, Changing physician prescribing patterns: evaluation of an educational strategy for acute diarrhea in Mexico City, Med Care, 32, 436, 10.1097/00005650-199405000-00003
Hristov, 1997, An active set algorithm for treatment planning optimization, Med Phys, 24, 1455, 10.1118/1.598034
Roland, 1995, A decision analysis of practice patterns used in evaluating and treating abnormal pap smears, Gynecol Oncol, 59, 75, 10.1006/gyno.1995.1270